New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:32 EDTACRX, VVUSAcelRx appoints Timothy Morris as CFO
AcelRx Pharmaceuticals (ACRX) announced the appointment of Timothy E. Morris as CFO. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of CFO, most recently operating in this capacity at VIVUS (VVUS). Morris will be responsible for managing the company's finance operations, its information systems and human resource and investor relations functions. Jim Welch, who had served as CFO since October 2010, departed the company to pursue other business opportunities.
News For ACRX;VVUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
16:15 EDTACRXOn The Fly: Closing Wrap
Stocks on Wall Street were higher, regaining much of their losses from yesterday, after GDP data showed the U.S. economy grew at its fastest pace in more than 2 years during the second quarter. Also helping improve sentiment was the significant earnings beat from Dow member Nike (NKE). ECONOMIC EVENTS: In the U.S., second quarter real GDP growth was revised up to 4.6% in the government's third estimate. This was raised from the prior 4.2% growth estimate, though the upward revision had been expected by analysts. The final University of Michigan consumer sentiment index for September came in at 84.6, which was unchanged from the preliminary print but up from the final August reading of 82.5. COMPANY NEWS: Shares of Nike climbed $9.75, or 12.23%, to $89.50 after the company reported stronger than expected results and provided better than expected profit guidance. Following last night's report, a number of analysts reacted positively in notes this morning, including Janney Capital, which upgraded the stock to Buy from Neutral. Meanwhile, Deutsche Bank upgraded Under Armour (UA) to Buy, citing continued sector strength evidenced in Nike's results. Under Armour gained $2.27, or 3.36%, to $69.82 following the report from the industry leader and Deutsche's ratings action. MAJOR MOVERS: Among the notable gainers was Janus Capital (JNS), which surged $4.60, or 41.43%, to $15.72 after the company unexpectedly announced that "Bond King" Bill Gross, formerly of PIMCO, will join as a fund manager this Monday. Afterward, Citigroup upgraded Janus to Neutral from Sell, citing Gross' hiring. Also higher was Yahoo (YHOO), which jumped $1.71, or 4.39%, to $40.66 after activist investor Starboard Value announced it has acquired a significant ownership stake in the company and urged it to explore a strategic combination with AOL (AOL). Shares of AOL also rose $1.58, or 3.68%, to $44.55 following Starboard's public disclosure of its recommendation to Yahoo. Among the noteworthy losers was Finish Line (FINL), which was left out of the Nike-fueled rally in the sneaker sector and fell $4.30, or 14.62%, to $25.11 after the company reported second quarter earnings and revenue that missed expectations. Following Finish Line's Q2 report, the stock and peer Foot Locker (FL) were both downgraded to Neutral from Buy at Bank of America Merrill Lynch. Also lower were shares of AcelRx (ACRX), which fell $1.31, or 19.49%, to $5.41 and was downgraded to Neutral at Roth Capital after the company said it has to resubmit for FDA approval of its Zalviso drug. INDEXES: The Dow advanced 167.35, or 0.99%, to 17,113.15, the Nasdaq gained 45.45, or 1.02%, to 4,512.19, and the S&P 500 rose 16.86, or 0.86%, to 1,982.85.
12:40 EDTACRXAcelRx downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
07:03 EDTACRXAcelRx provides update on resubmission of Zalviso NDA
Subscribe for More Information
September 18, 2014
16:27 EDTVVUSOn The Fly: Closing Wrap
Subscribe for More Information
14:09 EDTVVUSVIVUS rallies, mean-reverting to intraday trend line
The shares have traded in an extremely wide range today on nearly 20 times daily average volume. An intraday trend line appears currently to be broken. That line is at $4.60 now, and projecting forward would be at the $4.80 area by the close. At the current price of $4.50, support is at $4.41 and then at $4.32.
12:45 EDTVVUSOn The Fly: Midday Wrap
Subscribe for More Information
09:36 EDTVVUSActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL YHOO TWTR VVUS RAD PWE WFM TSLA PIR SHLD
08:59 EDTVVUSOn The Fly: Pre-market Movers
Subscribe for More Information
06:05 EDTVVUSVIVUS, Auxilium announce FDA approval of STENDRA sNDA
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has approved a supplemental new drug application, or sNDA, for STENDRA. STENDRA is now the only FDA-approved erectile dysfunction, or ED, medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a class of drugs known as phosphodiesterase type 5, or PDE5, inhibitors approved for the treatment of ED in men 18 years or older. STENDRA is available in multiple dosage strengths and may be taken with or without food and moderate alcohol consumption. In clinical studies, when compared to placebo, STENDRA helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use